Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Anoro® Ellipta® (umeclidinium/vilanterol).
Source: GSK news - Category: Pharmaceuticals Source Type: news